PHILADELPHIA – ERT, a global data and technology company dedicated to improving health outcomes through innovative drug development and patient support solutions, and Foundry3, a creative, science and innovation agency, today announced a partnership to create tailored digital health programs that improve clinical outcomes by providing support to patients throughout their health care journeys.
The partnership brings together the expertise of two organizations with distinct capabilities in driving digital health program success. Foundry3 adds its unique approach to uncovering the challenges and motivators that impact patient behaviors to ERT’s global expertise in delivering regulatory-compliant drug development and patient support solutions for the pharmaceutical industry. Together they will deliver rich, adaptive digital health programs ─ based on substantiated patient needs ─ to help patients better manage their conditions, ultimately improving health outcomes.
“At Foundry3 we listen to the voice of the patient to design successful digital health support initiatives based on positive behavior change, value to the patient and clinical relevance,” said Alex Butler, co-founder of Foundry3. “By partnering with ERT, we leverage their 50 years of scientific, clinical and technology expertise to provide the global scale, structure and governance needed to meet the pharmaceutical industry’s growing demand for more effective global patient support programs.”
“In order to optimize treatment effect and improve quality of life, support programs must be built around patients’ needs, a critical factor that’s been missing from some of the industry’s digital health initiatives,” said Tim Davis, vice president, digital patient, ERT. “Together with Foundry3, we are able to deliver tailored support programs that patients value because they’re built with patient insight and will truly improve people’s lives.”